Related Experiment Video
Updated: Jan 20, 2026

Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
Can serum GAD65 antibody levels predict neurological disease or cancer?
Henning K Olberg1, Geir E Eide2, Christian A Vedeler3
1Department of Neurology, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Norway.
Abstract:
The clinical relevance of antibodies that bind to glutamic acid decarboxylase 65 (GAD65) is controversial regarding diagnostic utility in screening for neurological disease or cancer. We did a retrospective study of 3152 GAD65 antibody-positive patients to examine whether analysis of the antibody levels could predict neurological disease or cancer. Serum GAD65 antibody levels were not associated with any of the following groups: neurological disease, neurological disease and diabetes, diabetes only, no neurological diagnosis and no diabetes mellitus, or cancer. Analysis of serum GAD65 antibody levels had no prognostic value in neurological disease or cancer. GAD65 antibodies should therefore be measured in selective cases of autoimmune neurological diseases.
Related Concept Videos
09:58Lipidomics and Transcriptomics in Neurological Diseases
06:56Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis
04:51Measuring Immunoglobulin G Levels Against a Test Vaccine in a Mouse Serum
08:52Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
05:33A Microneutralization Assay to Measure Neutralizing Antibody Titers in Human Serum
06:49A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

